Logo image of ACB

AURORA CANNABIS INC (ACB) Stock Fundamental Analysis

NASDAQ:ACB - Nasdaq - CA05156X8504 - Common Stock - Currency: USD

5.08  -0.31 (-5.75%)

After market: 5.0417 -0.04 (-0.75%)

Fundamental Rating

3

Overall ACB gets a fundamental rating of 3 out of 10. We evaluated ACB against 193 industry peers in the Pharmaceuticals industry. The financial health of ACB is average, but there are quite some concerns on its profitability. ACB has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ACB has reported negative net income.
In the past year ACB had a positive cash flow from operations.
In the past 5 years ACB reported 4 times negative net income.
In the past 5 years ACB reported 4 times negative operating cash flow.
ACB Yearly Net Income VS EBIT VS OCF VS FCFACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1B -2B -3B

1.2 Ratios

With an excellent Return On Assets value of 0.27%, ACB belongs to the best of the industry, outperforming 80.31% of the companies in the same industry.
Looking at the Return On Equity, with a value of 0.40%, ACB belongs to the top of the industry, outperforming 81.87% of the companies in the same industry.
Industry RankSector Rank
ROA 0.27%
ROE 0.4%
ROIC N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ACB Yearly ROA, ROE, ROICACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200 -250

1.3 Margins

With an excellent Profit Margin value of 0.66%, ACB belongs to the best of the industry, outperforming 80.83% of the companies in the same industry.
The Gross Margin of ACB (3.57%) is comparable to the rest of the industry.
ACB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 0.66%
GM 3.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
ACB Yearly Profit, Operating, Gross MarginsACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACB has been increased compared to 1 year ago.
The number of shares outstanding for ACB has been reduced compared to 5 years ago.
Compared to 1 year ago, ACB has an improved debt to assets ratio.
ACB Yearly Shares OutstandingACB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ACB Yearly Total Debt VS Total AssetsACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

Based on the Altman-Z score of -8.95, we must say that ACB is in the distress zone and has some risk of bankruptcy.
ACB has a Altman-Z score of -8.95. This is in the lower half of the industry: ACB underperforms 67.36% of its industry peers.
ACB has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
ACB has a Debt to Equity ratio of 0.14. This is comparable to the rest of the industry: ACB outperforms 48.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -8.95
ROIC/WACCN/A
WACC9.19%
ACB Yearly LT Debt VS Equity VS FCFACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

A Current Ratio of 4.31 indicates that ACB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.31, ACB is in the better half of the industry, outperforming 65.28% of the companies in the same industry.
A Quick Ratio of 2.16 indicates that ACB has no problem at all paying its short term obligations.
ACB's Quick ratio of 2.16 is in line compared to the rest of the industry. ACB outperforms 47.15% of its industry peers.
Industry RankSector Rank
Current Ratio 4.31
Quick Ratio 2.16
ACB Yearly Current Assets VS Current LiabilitesACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

ACB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.79%, which is quite impressive.
The Revenue has grown by 27.32% in the past year. This is a very strong growth!
Measured over the past years, ACB shows a small growth in Revenue. The Revenue has been growing by 6.94% on average per year.
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-307.69%
Revenue 1Y (TTM)27.32%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%17.48%

3.2 Future

The Earnings Per Share is expected to grow by 103.58% on average over the next years. This is a very strong growth
Based on estimates for the next years, ACB will show a small growth in Revenue. The Revenue will grow by 7.51% on average per year.
EPS Next Y578.72%
EPS Next 2Y242.29%
EPS Next 3Y192.26%
EPS Next 5Y103.58%
Revenue Next Year10.41%
Revenue Next 2Y7.87%
Revenue Next 3Y6.19%
Revenue Next 5Y7.51%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ACB Yearly Revenue VS EstimatesACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
ACB Yearly EPS VS EstimatesACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACB. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 11.96, the valuation of ACB can be described as very reasonable.
Based on the Price/Forward Earnings ratio, ACB is valued cheaply inside the industry as 82.90% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.34, ACB is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 11.96
ACB Price Earnings VS Forward Price EarningsACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACB Per share dataACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

ACB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ACB's earnings are expected to grow with 192.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y242.29%
EPS Next 3Y192.26%

More info and screens

0

5. Dividend

5.1 Amount

ACB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AURORA CANNABIS INC

NASDAQ:ACB (8/15/2025, 8:04:04 PM)

After market: 5.0417 -0.04 (-0.75%)

5.08

-0.31 (-5.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners19.7%
Inst Owner Change-26.9%
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap285.75M
Analysts73.33
Price Target6.43 (26.57%)
Short Float %10.95%
Short Ratio5.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2033.66%
Min EPS beat(2)-426.74%
Max EPS beat(2)4494.06%
EPS beat(4)2
Avg EPS beat(4)1031.37%
Min EPS beat(4)-426.74%
Max EPS beat(4)4494.06%
EPS beat(8)4
Avg EPS beat(8)477.85%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)7.36%
Min Revenue beat(2)0.93%
Max Revenue beat(2)13.79%
Revenue beat(4)4
Avg Revenue beat(4)9.09%
Min Revenue beat(4)0.93%
Max Revenue beat(4)14.66%
Revenue beat(8)7
Avg Revenue beat(8)6.06%
Revenue beat(12)7
Avg Revenue beat(12)2.42%
Revenue beat(16)9
Avg Revenue beat(16)2.12%
PT rev (1m)-8.61%
PT rev (3m)-15.78%
EPS NQ rev (1m)64.29%
EPS NQ rev (3m)-14.81%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5%
Revenue NY rev (1m)-0.98%
Revenue NY rev (3m)-0.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 11.96
P/S 1.15
P/FCF N/A
P/OCF 24.62
P/B 0.69
P/tB 0.82
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)0.42
Fwd EY8.36%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)0.21
OCFY4.06%
SpS4.43
BVpS7.31
TBVpS6.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.27%
ROE 0.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 0.66%
GM 3.57%
FCFM N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score7
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.64%
Cap/Sales 5.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.31
Quick Ratio 2.16
Altman-Z -8.95
F-Score7
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-307.69%
EPS Next Y578.72%
EPS Next 2Y242.29%
EPS Next 3Y192.26%
EPS Next 5Y103.58%
Revenue 1Y (TTM)27.32%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%17.48%
Revenue Next Year10.41%
Revenue Next 2Y7.87%
Revenue Next 3Y6.19%
Revenue Next 5Y7.51%
EBIT growth 1Y5.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year150.01%
EBIT Next 3Y29.94%
EBIT Next 5Y25.32%
FCF growth 1Y96.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y123.36%
OCF growth 3YN/A
OCF growth 5YN/A